Amylyx Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

AMLX$30.91+2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance as of December 31, 2025	109,884,502	$11	$1,056,271	$404	$(751,427)	$305,259
Issuance of common stock upon exercise of stock options	465,661	—	3,230	—	—	3,230
Issuance of common stock upon vesting of RSUs	676,314	—	—	—	—	—
Stock-based compensation expense	—	—	6,120	—	—	6,120
Other comprehensive loss	—	—	—	(164)	—	(164)
Net loss	—	—	—	—	(41,284)	(41,284)
Balance as of March 31, 2026	111,026,477	$11	$1,065,621	$240	$(792,711)	$273,161
Issuance of common stock upon exercise of stock options	256,272	—	1,332	—	—	1,332
Issuance of common stock upon vesting of RSUs	85,534	—	—	—	—	—
Stock-based compensation expense	—	—	8,318	—	—	8,318
Other comprehensive loss	—	—	—	(221)	—	(221)
Net loss	—	—	—	—	(43,423)	(43,423)
Balance as of June 30, 2026	111,368,283	$11	$1,075,271	$19	$(836,134)	$239,167
Issuance of common stock upon financing, net of issuance costs	16,203,500	2	$544,567	$—	$—	544,569
Issuance of common stock upon exercise of stock options	519,914	—	5,316	—	—	5,316
Issuance of common stock upon vesting of RSUs and PSUs	452,505	—	—	—	—	—
Stock-based compensation expense	—	—	10,371	—	—	10,371
Other comprehensive income	—	—	—	(198)	—	(198)
Net loss	—	—	—	—	(45,489)	(45,489)
Balance as of September 30, 2026	128,544,202	$13	$1,635,525	$(179)	$(881,623)	$753,736

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance as of December 31, 2024	68,629,738	$7	$771,542	$(92)	$(606,692)	$164,765
Issuance of common stock upon financing, net of issuance costs	19,714,285	2	65,575	—	—	65,577
Issuance of common stock upon exercise of stock options	36,310	—	57	—	—	57
Issuance of common stock upon vesting of RSUs	700,488	—	—	—	—	—
Stock-based compensation expense	—	—	6,833	—	—	6,833
Other comprehensive income	—	—	—	92	—	92
Net loss	—	—	—	—	(35,907)	(35,907)
Balance as of March 31, 2025	89,080,821	$9	$844,007	$—	$(642,599)	$201,417
Issuance of common stock upon exercise of stock options	855	—	2	—	—	2
Issuance of common stock upon vesting of RSUs	74,674	—	—	—	—	—
Stock-based compensation expense	—	—	7,350	—	—	7,350
Other comprehensive income	—	—	—	551	—	551
Net loss	—	—	—	—	(41,443)	(41,443)
Balance as of June 30, 2025	89,156,350	$9	$851,359	$551	$(684,042)	$167,877
Issuance of common stock upon financing, net of issuance costs	20,125,000	2	190,735	—	—	190,737
Issuance of common stock upon exercise of stock options	95,787	—	428	—	—	428
Issuance of common stock upon vesting of RSUs	389,245	—	—	—	—	—
Stock-based compensation expense	—	—	7,076	—	—	7,076
Other comprehensive income	—	—	—	264	—	264
Net loss	—	—	—	—	(34,386)	(34,386)
Balance as of September 30, 2025	109,766,382	$11	$1,049,598	$815	$(718,428)	$331,996

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.